Responses
Immunotherapy biomarkers
Original research
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors
Compose a Response to This Article
Other responses
No responses have been published for this article.